Chemogenomics for Drug Discovery: Clinical Molecules from Open Access Chemical Probes

Overview

Journal RSC Chem Biol

Publisher Royal Society of Chemistry

Specialty Biology

Date 2021 Aug 30

PMID 34458810

Citations 5

Authors

Robert B A Quinlan

Paul E Brennan

Affiliations

Soon will be listed here.

Abstract

In recent years chemical probes have proved valuable tools for the validation of disease-modifying targets, facilitating investigation of target function, safety, and translation. Whilst probes and drugs often differ in their properties, there is a belief that chemical probes are useful for translational studies and can accelerate the drug discovery process by providing a starting point for small molecule drugs. This review seeks to describe clinical candidates that have been inspired by, or derived from, chemical probes, and the process behind their development. By focusing primarily on examples of probes developed by the Structural Genomics Consortium, we examine a variety of epigenetic modulators along with other classes of probe.

Citing Articles

SETDB1 as a cancer target: challenges and perspectives in drug design.

Hassanie H, Penteado A, de Almeida L, Calil R, da Silva Emery F, Costa-Lotufo L RSC Med Chem. 2024; 15(5):1424-1451.

PMID: 38799223 PMC: 11113007. DOI: 10.1039/d3md00366c.

Editorial: Computational chemogenomics: In silico tools in pharmacological research and drug discovery.

Sanchez-Cruz N, Fernandez-de Gortari E, Medina-Franco J Front Pharmacol. 2023; 14:1150869.

PMID: 37007046 PMC: 10064217. DOI: 10.3389/fphar.2023.1150869.

A review on computer-aided chemogenomics and drug repositioning for rational COVID-19 drug discovery.

Maghsoudi S, Taghavi Shahraki B, Rameh F, Nazarabi M, Fatahi Y, Akhavan O Chem Biol Drug Des. 2022; 100(5):699-721.

PMID: 36002440 PMC: 9539342. DOI: 10.1111/cbdd.14136.

Target 2035 - update on the quest for a probe for every protein.

Muller S, Ackloo S, Al Chawaf A, Al-Lazikani B, Antolin A, Baell J RSC Med Chem. 2022; 13(1):13-21.

PMID: 35211674 PMC: 8792830. DOI: 10.1039/d1md00228g.

Advances in the Exploration of the Epigenetic Relevant Chemical Space.

Prado-Romero D, Medina-Franco J ACS Omega. 2021; 6(35):22478-22486.

PMID: 34514220 PMC: 8427648. DOI: 10.1021/acsomega.1c03389.

References

Nayak S, Panesar P, Kumar H . p53-Induced apoptosis and inhibitors of p53. Curr Med Chem. 2009; 16(21):2627-40. DOI: 10.2174/092986709788681976. View

Mujtaba S, He Y, Zeng L, Yan S, Plotnikova O, Sachchidanand . Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell. 2004; 13(2):251-63. DOI: 10.1016/s1097-2765(03)00528-8. View

Huang J, Dorsey J, Chuikov S, Zhang X, Jenuwein T, Reinberg D . G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem. 2010; 285(13):9636-9641. PMC: 2843213. DOI: 10.1074/jbc.M109.062588. View

Genin M, Bueno A, Agejas Francisco J, Manninen P, Bocchinfuso W, Montrose-Rafizadeh C . Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia. J Med Chem. 2015; 58(24):9768-72. DOI: 10.1021/acs.jmedchem.5b01161. View

Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield V . hDOT1L links histone methylation to leukemogenesis. Cell. 2005; 121(2):167-78. DOI: 10.1016/j.cell.2005.02.020. View

Dyson J, Hirschfield G, Adams D, Beuers U, Mann D, Lindor K . Novel therapeutic targets in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol. 2015; 12(3):147-58. DOI: 10.1038/nrgastro.2015.12. View

Pappano W, Guo J, He Y, Ferguson D, Jagadeeswaran S, Osterling D . The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia. PLoS One. 2015; 10(7):e0131716. PMC: 4492996. DOI: 10.1371/journal.pone.0131716. View

Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry M . Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2013; 123(5):697-705. DOI: 10.1182/blood-2013-01-478420. View

Vazquez R, Riveiro M, Astorgues-Xerri L, Odore E, Rezai K, Erba E . The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget. 2016; 8(5):7598-7613. PMC: 5352346. DOI: 10.18632/oncotarget.13814. View

10.

Hong H, Kao C, Jeng M, Eble J, Koch M, Gardner T . Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer. 2004; 101(1):83-9. DOI: 10.1002/cncr.20327. View

11.

Sarkozy C, Morschhauser F, Dubois S, Molina T, Michot J, Cullieres-Dartigues P . A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. Clin Cancer Res. 2020; 26(13):3145-3153. DOI: 10.1158/1078-0432.CCR-19-3741. View

12.

Krivtsov A, Armstrong S . MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007; 7(11):823-33. DOI: 10.1038/nrc2253. View

13.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

14.

Ding L, Pang S, Sun Y, Tian Y, Yu L, Dang N . Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes. Int J Endocrinol. 2014; 2014:751859. PMC: 4020365. DOI: 10.1155/2014/751859. View

15.

Thornberry N, Weber A . Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem. 2007; 7(6):557-68. DOI: 10.2174/156802607780091028. View

16.

Weiss W, Taylor S, Shokat K . Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol. 2007; 3(12):739-44. PMC: 2924165. DOI: 10.1038/nchembio1207-739. View

17.

Chung C, Dean A, Woolven J, Bamborough P . Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J Med Chem. 2011; 55(2):576-86. DOI: 10.1021/jm201320w. View

18.

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

19.

Paul C, Sardet C, Fabbrizio E . The Wnt-target gene Dlk-1 is regulated by the Prmt5-associated factor Copr5 during adipogenic conversion. Biol Open. 2015; 4(3):312-6. PMC: 4359737. DOI: 10.1242/bio.201411247. View

20.

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View